日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

复发/难治性慢性淋巴细胞白血病对吡托布替尼的反应和耐药性的基因组决定因素

Brown, Jennifer R; Nguyen, Bastien; Desikan, Sai Prasad; Won, Helen; Tantawy, Shady I; McNeely, Samuel C; Marella, Narasimha; Randeria, Hetal S; Hanson, Lauren M; Parker, Andrew; Botelho, Salomé Calado; Woyach, Jennifer A; Patel, Krish; Tam, Constantine S; Eyre, Toby A; Cheah, Chan Y; Shah, Nirav N; Ghia, Paolo; Jurczak, Wojciech; Balbas, Minna; Nair, Binoj; Abada, Paolo; Wang, Chunxiao; Wang, Denise; Roeker, Lindsey E; Gandhi, Varsha; Wierda, William G

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥洛莫拉西布(一种新一代 KRAS G12C 抑制剂)在 KRAS G12C 突变型晚期实体瘤中的泛肿瘤活性:一项首次人体研究

Murciano-Goroff, Yonina R; Hollebecque, Antoine; Heist, Rebecca S; Cassier, Philippe A; Han, Ji-Youn; Kim, So Yeon; Sabari, Joshua K; Tosi, Diego; Sacher, Adrian; Burns, Timothy F; Shimizu, Toshio; Reddy Ammakkanavar, Natraj; Spira, Alexander; Gomez-Roca, Carlos; Patnaik, Amita; Cosman, Rasha; Bodor, J Nicholas; Nagasaka, Misako; You, Arthur Xintian; McNeely, Samuel C; Peter, Raimund; Fink, Aaron; Chen, Aaron; Oxnard, Geoffrey R; Willard, Melinda D; Kuboki, Yasutoshi; Koyama, Takafumi

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

在复发/难治性慢性淋巴细胞白血病 (CLL) 患者中,固定疗程的吡布替尼联合维奈克拉,加或不加利妥昔单抗:1b 期 BRUIN 试验

Roeker, Lindsey E; Woyach, Jennifer A; Cheah, Chan Y; Coombs, Catherine C; Shah, Nirav N; Wierda, William G; Patel, Manish R; Lamanna, Nicole; Tsai, Donald E; Nair, Binoj; Wang, Chunxiao; Zhao, Xiang; Liu, Dan; Radtke, David; Chapman, Sonya; Marella, Narasimha; McNeely, Samuel C; Brown, Jennifer R

A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors

LY3405105(一种细胞周期蛋白依赖性激酶 7 的共价抑制剂)治疗晚期实体瘤患者的 I 期剂量递增研究

Garralda, Elena; Schram, Alison M; Bedard, Philippe L; Schwartz, Gary K; Yuen, Eunice; McNeely, Samuel C; Ribeiro, Silvia; Cunningham, Jason; Wang, Yi; Urunuela, Arantxa; Xu, Xiaojian; LoRusso, Patricia

Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy

抑制p53和p21CIP1/WAF1可减少亚砷酸盐诱导的非整倍体

Salazar, Ana María; Miller, Heather L; McNeely, Samuel C; Sordo, Monserrat; Ostrosky-Wegman, Patricia; States, J Christopher

Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest

人类黑色素瘤细胞对亚砷酸钠的敏感性取决于其对亚砷酸盐诱导的有丝分裂阻滞的敏感性。

McNeely, Samuel C; Belshoff, Alex C; Taylor, B Frazier; Fan, Teresa W-M; McCabe, Michael J Jr; Pinhas, Allan R; States, J Christopher

Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent

亚砷酸钠诱导A375黑色素瘤细胞发生有丝分裂阻滞相关的细胞凋亡是BUBR1依赖性的。

McNeely, Samuel C; Taylor, B Frazier; States, J Christopher

Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.

亚砷酸盐诱导的有丝分裂死亡涉及应激反应,并且与微管蛋白聚合无关

Taylor B Frazier, McNeely Samuel C, Miller Heather L, States J Christopher